Product Description
Nedocromil sodium, the disodium salt of a pyranoquinoline dicarboxylic acid, has anti-inflammatory properties in vitro, in animal models of asthma, and in humans, as evidenced by inhibition of inflammatory cell activation and mediator release, early and late allergen-induced bronchoconstriction and airway hyperresponsiveness. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/7686465/)
Mechanisms of Action: Histamine Antagonist,PGD2 Antagonist,LT Antagonist,GPR Agonist,Glucuronidase Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Inhalant
FDA Designation: None *
Approval Status: Approved
Approved Countries: Brazil | Canada | Colombia | Denmark | Egypt | France | Germany | Ireland | Italy | New Zealand | Pakistan | Peru | Portugal | Russia | Sweden | Taiwan | Turkey | United Kingdom | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|